Beatriz Carvalho

Senior scientist

The Netherlands Cancer Institute
Country flagNetherlands

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (9)

Year:

2026

Year:

2025

Year:

2025

Up to 30% of colorectal cancers (CRCs) develop from sessile serrated lesions (SSLs). Within the serrated neoplasia pathway, at least two principally distinct oncogenetic routes exist generating microsatellite‐stable and microsatellite‐instable CRCs, respectively. Aberrant DNA methylation (DNAm) is found early in the serrated pathway and might play a role in both oncogenetic routes. We studied a cohort of 23 SSLs with a small focus (<10 mm) of dysplasia or cancer, 10 of which were MLH1 deficient and 13 MLH1 proficient. By comparing, for each SSL, the methylation status of (1) the region of dysplasia or cancer (SSL‐D), (2) the nondysplastic SSL (SSL), and (3) adjacent normal mucosa, differentially methylated probes (DMPs) and regions (DMRs) were assessed both genome‐wide as well as in a tumor‐suppressor gene‐focused approach. By comparing DNAm of MLH1‐deficient SSL‐Ds with their corresponding SSLs, we identified five DMRs, including those annotating for PRDM2 and, not unexpectedly, MLH1 . PRDM2 gene promotor methylation was associated with MLH1 expression status, as it was largely hypermethylated in MLH1‐deficient SSL‐Ds and hypomethylated in MLH1‐proficient SSL‐Ds. Significantly increased DNAm levels of PRDM2 and MLH1 , in particular at ‘critical’ MLH1 probe sites, were to some extent already visible in SSLs as compared to normal mucosa ( p = 0.02, p = 0.01, p < 0.0001, respectively). No DMRs, nor DMPs, were identified for SSLs destined to evolve into MLH1‐proficient SSL‐Ds. Our data indicate that, within both arms of the serrated CRC pathway, the majority of the epigenetic alterations are introduced early during SSL formation. Promoter hypermethylation of PRDM2 and MLH1 on the other hand specifically initiates in SSLs destined to transform into MLH1‐deficient CRCs suggesting that the fate of SSLs may not necessarily result from a stochastic process but possibly is already imprinted and predisposed.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Collaborators (13)

Robert JC Steele

Research Professor

-

UNITED KINGDOM
View details

Gerrit Meijer

Professor of Oncologic Pathology

University Medical Center Groningen

NETHERLANDS
View details

Robert Bresalier

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Dimitrios Mathios

Assistant Professor

Washington University in St. Louis

UNITED STATES
View details

Claus Lindbjerg Andersen

VIP, Professor

Aarhus University

DENMARK
View details

Graeme Young

Flinders University

AUSTRALIA
View details

Evelien Dekker

Professor

Amsterdam University Medical Centers

NETHERLANDS
View details

Lydia GUITTET

Université de Caen Normandie

FRANCE
View details

Ronny Drapkin

Franklin Payne Professor of Pathology in Obstetrics and Gynecology

University of Pennsylvania

UNITED STATES
View details

Lana Meiqari

University of Amsterdam

NETHERLANDS
View details

Carel JM van Noesel

Amsterdam University Medical Centers

NETHERLANDS
View details

Beatrice Lauby-Secretan

Head, IARC Handbooks Programme

International Agency for Research on Cancer

FRANCE
View details

Soufyan Lakbir

Utrecht University

NETHERLANDS
View details